- Home
- EPAM vs LEGN Comparison
EPAM vs LEGN Comparison
Compare EPAM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- LEGN
- Stock Information
- Founded
- EPAM 1993
- LEGN 2014
- Country
- EPAM United States
- LEGN United States
- Employees
- EPAM N/A
- LEGN N/A
- Industry
- EPAM EDP Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EPAM Technology
- LEGN Health Care
- Exchange
- EPAM Nasdaq
- LEGN Nasdaq
- Market Cap
- EPAM 8.2B
- LEGN 5.4B
- IPO Year
- EPAM 2012
- LEGN 2020
- Fundamental
- Price
- EPAM $169.03
- LEGN $39.34
- Analyst Decision
- EPAM Buy
- LEGN Strong Buy
- Analyst Count
- EPAM 14
- LEGN 12
- Target Price
- EPAM $231.43
- LEGN $73.91
- AVG Volume (30 Days)
- EPAM 612.8K
- LEGN 1.6M
- Earning Date
- EPAM 08-07-2025
- LEGN 08-08-2025
- Dividend Yield
- EPAM N/A
- LEGN N/A
- EPS Growth
- EPAM N/A
- LEGN N/A
- EPS
- EPAM 7.15
- LEGN N/A
- Revenue
- EPAM $4,864,167,000.00
- LEGN $728,303,000.00
- Revenue This Year
- EPAM $15.44
- LEGN $65.49
- Revenue Next Year
- EPAM $7.38
- LEGN $53.76
- P/E Ratio
- EPAM $23.75
- LEGN N/A
- Revenue Growth
- EPAM 4.72
- LEGN 112.46
- 52 Week Low
- EPAM $138.15
- LEGN $27.34
- 52 Week High
- EPAM $269.00
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- EPAM 45.16
- LEGN 66.83
- Support Level
- EPAM $158.54
- LEGN $38.86
- Resistance Level
- EPAM $185.82
- LEGN $39.88
- Average True Range (ATR)
- EPAM 4.55
- LEGN 1.41
- MACD
- EPAM 0.08
- LEGN 0.34
- Stochastic Oscillator
- EPAM 44.34
- LEGN 90.21
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.